CO2022003543A2 - Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina - Google Patents

Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina

Info

Publication number
CO2022003543A2
CO2022003543A2 CONC2022/0003543A CO2022003543A CO2022003543A2 CO 2022003543 A2 CO2022003543 A2 CO 2022003543A2 CO 2022003543 A CO2022003543 A CO 2022003543A CO 2022003543 A2 CO2022003543 A2 CO 2022003543A2
Authority
CO
Colombia
Prior art keywords
long
injectable formulations
acting injectable
ketamine pamoate
pamoate salts
Prior art date
Application number
CONC2022/0003543A
Other languages
English (en)
Inventor
Tong-Ho Lin
Yung-Shun Wen
Chia-Hsien Chen
Ying-Ting Liu
rui-zhi Hou
zhi-rong Wu
Original Assignee
Alar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc filed Critical Alar Pharmaceuticals Inc
Publication of CO2022003543A2 publication Critical patent/CO2022003543A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas de liberación sostenida que incluyen una sal de pamoato de ketamina y un portador farmacéuticamente aceptable de la misma. Las composiciones incluyen suspensión acuosa, solución y sistema de administración de matriz, que pueden proporcionar una liberación sostenida para anestesia, analgesia o tratamiento del sistema nervioso central y enfermedades antiinflamatorias.
CONC2022/0003543A 2019-12-20 2022-03-25 Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina CO2022003543A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951061P 2019-12-20 2019-12-20
PCT/CN2020/137496 WO2021121366A1 (en) 2019-12-20 2020-12-18 Long-acting injectable formulations of ketamine pamoate salts

Publications (1)

Publication Number Publication Date
CO2022003543A2 true CO2022003543A2 (es) 2022-04-19

Family

ID=76478186

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0003543A CO2022003543A2 (es) 2019-12-20 2022-03-25 Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina

Country Status (15)

Country Link
US (1) US20240099994A1 (es)
EP (1) EP4076410A4 (es)
JP (1) JP2023505963A (es)
KR (1) KR20220118427A (es)
AR (1) AR120816A1 (es)
AU (1) AU2020410549A1 (es)
BR (1) BR112022012255A2 (es)
CA (1) CA3152593A1 (es)
CL (1) CL2022001636A1 (es)
CO (1) CO2022003543A2 (es)
IL (1) IL294089A (es)
MX (1) MX2022006596A (es)
PE (1) PE20231942A1 (es)
TW (1) TW202135782A (es)
WO (1) WO2021121366A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
CA3099293A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2023178039A1 (en) * 2022-03-14 2023-09-21 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968221T3 (pl) * 2013-03-15 2020-01-31 Janssen Pharmaceutica Nv Kompozycja farmaceutyczna chlorowodorku S-ketaminy
CN110325179A (zh) * 2016-12-26 2019-10-11 塞尔利克斯生物私人有限公司 用于治疗慢性疼痛的组合物和方法
CA3077645A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. A solid extended-release pharmaceutical formulations comprising ketamine or norketamine
WO2019172920A1 (en) * 2018-03-09 2019-09-12 Rk Pharmaceuticals, Llc Injectable composition for controlled-release of active ingredient to manage postoperative pain or neuropathic back pain
EP3761970A4 (en) * 2018-03-26 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
LT3908570T (lt) * 2019-01-11 2024-03-12 Alar Pharmaceuticals Inc. Ketamino pamoatas ir jo naudojimas

Also Published As

Publication number Publication date
EP4076410A4 (en) 2024-02-07
PE20231942A1 (es) 2023-12-05
WO2021121366A1 (en) 2021-06-24
KR20220118427A (ko) 2022-08-25
BR112022012255A2 (pt) 2022-08-30
CA3152593A1 (en) 2021-06-24
AR120816A1 (es) 2022-03-23
CL2022001636A1 (es) 2023-01-27
CN114340603A (zh) 2022-04-12
JP2023505963A (ja) 2023-02-14
US20240099994A1 (en) 2024-03-28
IL294089A (en) 2022-08-01
TW202135782A (zh) 2021-10-01
MX2022006596A (es) 2022-07-05
AU2020410549A1 (en) 2022-04-14
EP4076410A1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
CO2022003543A2 (es) Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
UY37686A (es) Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
AR109590A2 (es) Régimen posológico para inhibidores de comt
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
UY36124A (es) Derivados de carboxamida
UY39150A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
UY36123A (es) Derivados de carboxamida
CO2022005926A2 (es) Inhibidores del factor d del complemento para administración oral
PH12021550406A1 (en) Fused ring derivative used as fgfr4 inhibitor
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR064727A1 (es) Derivados de [1,8]naftiridin-2-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos asociados al snc.
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
UA120764U (uk) Лікарський препарат знеболювальної та спазмолітичної дії "фентаніл"
AR110319A1 (es) Composición para el tratamiento de la osteoartritis
CU20160170A7 (es) Derivados de carboxamida